Previous 10 | Next 10 |
KalVista Pharmaceticals (KALV): Q2 GAAP EPS of -$0.58 beats by $0.09.Cash, cash equivalents and marketable securities were $55.9 million as of October 31, 2020, compared to $67.7 million as of April 30, 2020.Press Release For further details see: KalVista Pharmaceticals EPS beats by $0....
– KVD900 Phase 2 Clinical Trial Patient Treatment Completed; Data Expected Q1 2021 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease i...
Despite flunking a Phase 2 trial for its diabetic macular edema asset (KVD001), KalVista Pharmaceuticals' stock has remained steady, except for a brief coronavirus related plunge. Investors are more focused on the results of a KVD900 Phase 2 trial for patients with hereditary angioede...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will present a corporate overview at the following investor conferences: St...
Thinly traded micro cap KalVista Pharmaceuticals (KALV) has issued pipeline update for investors. Key points:KVD900: Concluded enrollment of Phase 2 trial, and remain on track to announce data by end of this year.KVD824: Achieved targeted exposure levels for prophylaxis, IND su...
KalVista Pharmaceticals (NASDAQ: KALV ) : FQ1 GAAP EPS of -$0.61 misses by $0.01 . Cash, cash equivalents and marketable securities were $64.3M. Press Release More news on: KalVista Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
– KVD900 On-Demand Data Expected Q4 2020 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and r...
The following slide deck was published by KalVista Pharmaceuticals, Inc. in conjunction with this Read more ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 20...
KalVista Pharmaceticals (NASDAQ: KALV ): Q4 GAAP EPS of -$0.37 beats by $0.28 . More news on: KalVista Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...